YPYoonhee Park

Yoonhee Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoonhee Park has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Hee Joon Yoo

    Department of Biotechnology, College of Life Science and Biotechnology, Korea University, Seoul 02841, Korea

    1 shared publication
  • Jiyeon Yang

    Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea

    1 shared publication
  • Jun Gu Oh

    Department of Biotechnology, College of Life Sciences and Biotechnology, 02841, Korea University, Seoul, Republic of Korea

    1 shared publication
  • Jung-Il Kwon

    Department of Integrated Biomedical and Life Science, Graduate School, 02841, Korea University, Seoul, Republic of Korea

    1 shared publication
  • Kwang-Won Lee

    Department of Biotechnology, Korea University, Seoul 02841, Republic of Korea

    1 shared publication
  • Sewon Park

    Department of Biotechnology, College of Life Sciences and Biotechnology, 02841, Korea University, Seoul, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    Combining 2′-fucosyllactose and galacto-oligosaccharides exerts anti-inflammatory effects and promotes gut health

    by Sewon Park, Yoonhee Park, Yu-Jin Jeong, Jun Gu Oh, Hee Joon Yoo, Jiyeon Yang, Jung-Il Kwon, Kwang-Won Lee

    This study investigated the potential of 2'-Fucosyllactose (2'-FL) and galactooligosaccharides (GOS) combinations as a novel and cost-effective substitute for human milk oligosaccharides (HMOs) in promoting gut health and reducing inflammation. In vitro studies using Caco-2 cells showed that 2'-FL and GOS combinations (H1: GOS:2'-FL ratio of 1.8:1; H2: ratio of 3.6:1) reduced lipopolysaccharide-induced inflammation by decreasing pro-inflammatory markers, while individual treatments had no significant effects. In a mouse model of dextran sulfate sodium (DSS)-induced colitis, combined 2'-FL and GOS supplementation alleviated symptoms, improved gut permeability, and enhanced intestinal structure, with the GH1 group (H1 combo with DSS) being the most effective. 2'-FL and GOS combinations also enhanced short-chain fatty acid production in infant fecal batch fermentation and mouse fecal analysis, with GH1 showing the most promising results. GH1 supplementation altered gut microbiota in mice with DSS-induced colitis, promoting microbial diversity and a more balanced Firmicutes to Bacteroidota ratio. Infant formula products (IFPs) containing 2'-FL and GOS combinations (IFP2: 174 mg GOS and 95 mg 2'-FL per 14 g serving, 1.8:1 ratio; IFP3: 174 mg GOS and 48 mg 2'-FL per 14 g serving, 3.6:1 ratio) demonstrated gastrointestinal protective and anti-inflammatory properties in a coculture model of Caco-2 and THP-1 cells. These findings suggest that 2'-FL and GOS combinations have potential applications in advanced infant formulas and supplements to promote gut health and reduce inflammation.